April 30, 2007Journal of Clinical Oncology1,999 citations
View Full PaperOpen-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
Key Points
- To evaluate the efficacy of panitumumab in improving progression-free survival in patients with chemotherapy-refractory metastatic colorectal cancer.
- Open-label phase III trial comparing panitumumab plus best supportive care to best supportive care alone.
- Patient population consisted of those with chemotherapy-refractory metastatic colorectal cancer.
- Evaluated toxicity and efficacy of panitumumab.
- Panitumumab significantly improved progression-free survival compared to best supportive care alone.
- Toxicity was manageable, indicating that panitumumab may be a viable treatment option.
Abstract
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer.